Nanobiosym Health RADAR, a US-based research incubator institute, has been awarded the $525,000 grand prize for its Gene-RADAR sensing technology in the first $2.25m Nokia Sensing XCHALLENGE.
The platform was awarded for its rapid ability to detect the presence or absence of a disease's pathogen by analysing a drop of blood, saliva or other body fluid placed on a nanochip and inserted into a mobile device.
In addition, the Gene-RADAR technology advances personalised diagnostic testing by delivering results in a short space of time, but with the same accuracy available only in a diagnostic lab.
Gene-RADAR technology is also primed for widespread use in developing countries due to being easy-to-use and does not need overhead infrastructure such as electricity or running water.
The competition was conducted by the XPRIZE Foundation and sponsored by Nokia.
XPRIZE Foundation vice-chairman and president Robert K Weiss said: "The future of digital medical technology illuminated by Nanobiosym exemplifies the goal of the Nokia Sensing XCHALLENGE, to advance innovative sensing technologies that will help transform health care into a 'smart', highly personalised and instantly accessible system."
In this first competition, Nanobiosym had competed with 26 teams from seven countries.
From this group, 12 finalist teams were selected who demonstrated the sensing capabilities of their technologies to a judging panel consisting of leaders from the fields of sensing and mobile health technologies during the Health 2.0 Fall Conference.
Nokia chief technology officer and executive vice-president Henry Tirri said the technologies demonstrated by the teams show the potential for sensors to bring greater efficiency, reliability and affordability to the health care system.
"We are taking a significant step towards creating an ecosystem of innovative technologies that will radically change the way people understand their state of health," Tirri said.
The 12 finalists were evaluated for their distinction in the areas of accuracy and consistency, demonstration quality, technical innovation, human factors, market opportunity, originality, and user experience.
In the final round of judging, five prizes each valued at $120,000 were awarded to Owlstone, InSilixa, Silcon BioDevices, Elfi-Tech and MoboSens.
Nanobiosym has previously created custom applications for E. coli and HIV/AIDS with potential applications across the entire band of health care including diagnosis, monitoring, drug development, companion diagnostics, and personalised nanomedicine.
Image: Dr Anita Goel, team leader for Nanobiosym Health RADAR, demonstrates her team's winning technology in the Nokia Sensing XCHALLENGE at Health 2.0. Photo: courtesy of Marketwired.